Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
3.
J Ren Nutr ; 23(5): e89-95, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23046736

RESUMO

OBJECTIVE: Testosterone deficiency is a common finding in men with chronic kidney disease (CKD). Testosterone is thought to play an important anabolic role in muscle synthesis, and muscle wasting is an important and deleterious characteristic of protein-energy wasting (PEW) in CKD. It is presently unknown if reduced endogenous testosterone associates with features of muscle wasting in men with CKD. METHODS: This was a cross-sectional observational study of 267 men with CKD stages 2-4 (mean ± standard deviation age 67 ± 13 years, estimated glomerular filtration rate 42.9 [interquartile range 30.2-56.7] mL/min/1.73 m²) with measurements of endogenous testosterone and surrogates of PEW such as albumin, prealbumin, high-sensitivity C-reactive protein (CRP) and normalized protein nitrogen appearance (nPNA). Fat-free mass was estimated by bioelectrical impedance vector analysis (BIVA) and muscle strength by handgrip dynamometry. RESULTS: Across decreasing thirds of testosterone distribution, patients were incrementally older and CRP levels rose significantly. Prealbumin, hemoglobin, nPNA, handgrip strength, and BIVA estimated surrogates of muscle mass and nutritional status (fat-free mass, body cell mass, and phase angle) were progressively reduced (P < .05 for all). In multivariate regression analyses including age, renal function, and other important confounders, testosterone significantly and independently contributed to explain the variances of handgrip strength and fat-free mass (P < .05 for all). CONCLUSIONS: Endogenous testosterone independently associates with muscle strength and fat-free mass in men with moderate CKD. It is plausible that the reduction in testosterone levels that accompanies CKD may further contribute to the procatabolic environment leading to muscle wasting.


Assuntos
Índice de Massa Corporal , Força da Mão/fisiologia , Insuficiência Renal Crônica/sangue , Testosterona/sangue , Idoso , Idoso de 80 Anos ou mais , Peso Corporal , Proteína C-Reativa/metabolismo , Estudos Transversais , Impedância Elétrica , Taxa de Filtração Glomerular , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estado Nutricional , Fenótipo , Estudos Prospectivos , Análise de Regressão , Insuficiência Renal Crônica/fisiopatologia , Fatores de Risco , Testosterona/deficiência
5.
Enferm Infecc Microbiol Clin ; 28(10): 759-61; author reply 761-2., 2010 Dec.
Artigo em Espanhol | MEDLINE | ID: mdl-20826041
6.
Ther Apher Dial ; 14(3): 368-72, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20609194

RESUMO

Unlike Goodpasture's syndrome with diffuse alveolar hemorrhage (DAH), there are scarce reports on the use of plasmapheresis for patients with a recurrence of DAH associated with antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis (AAV) on hemodialysis. We report a case of a relapse of perinuclear-AAV with DAH, five months after starting hemodialysis. The patient received apheresis and induction immunosuppressive therapy, added to a short course of daily hemodialysis treatments. The DAH resolved with seven apheresis procedures and there were no adverse effects. We suggest that patients on hemodialysis with a relapse of AAV and DAH would benefit from the prompt initiation of apheresis in combination with aggressive immunosuppressive therapy. Pulmonary hemorrhage is not included in the current guidelines for therapeutic apheresis; therefore, we report this case and, if warranted, propose this condition to be included in the guidelines.


Assuntos
Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/terapia , Hemorragia/terapia , Plasmaferese/métodos , Idoso , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/complicações , Hemorragia/etiologia , Humanos , Masculino , Alvéolos Pulmonares/patologia , Recidiva , Diálise Renal
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...